Literature DB >> 15728897

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae.

Alexey Ruzin1, Melissa A Visalli, David Keeney, Patricia A Bradford.   

Abstract

Tigecycline is an expanded broad-spectrum antibacterial agent that is active against many clinically relevant species of bacterial pathogens, including Klebsiella pneumoniae. The majority of K. pneumoniae isolates are fully susceptible to tigecycline; however, a few strains that have decreased susceptibility have been isolated. One isolate, G340 (for which the tigecycline MIC is 4 microg/ml and which displays a multidrug resistance [MDR] phenotype), was selected for analysis of the mechanism for this decreased susceptibility by use of transposon mutagenesis with IS903phikan. A tigecycline-susceptible mutant of G340, GC7535, was obtained (tigecycline MIC, 0.25 microg/ml). Analysis of the transposon insertion mapped it to ramA, a gene that was previously identified to be involved in MDR in K. pneumoniae. For GC7535, the disruption of ramA led to a 16-fold decrease in the MIC of tigecycline and also a suppression of MDR. Trans-complementation with plasmid-borne ramA restored the original parental phenotype of decreased susceptibility to tigecycline. Northern blot analysis revealed a constitutive overexpression of ramA that correlated with an increased expression of the AcrAB transporter in G340 compared to that in tigecycline-susceptible strains. Laboratory mutants of K. pneumoniae with decreased susceptibility to tigecycline could be selected at a frequency of approximately 4 x 10(-8). These results suggest that ramA is associated with decreased tigecycline susceptibility in K. pneumoniae due to its role in the expression of the AcrAB multidrug efflux pump.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728897      PMCID: PMC549240          DOI: 10.1128/AAC.49.3.1017-1022.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 2.  Efflux pumps: their role in antibacterial drug discovery.

Authors:  O Lomovskaya; W J Watkins
Journal:  Curr Med Chem       Date:  2001-12       Impact factor: 4.530

3.  A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences.

Authors:  T Triglia; M G Peterson; D J Kemp
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

4.  The distribution of the numbers of mutants in bacterial populations.

Authors:  D E LEA; C A COULSON
Journal:  J Genet       Date:  1949-12       Impact factor: 1.166

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Direct selection of IS903 transposon insertions by use of a broad-host-range vector: isolation of catalase-deficient mutants of Actinobacillus actinomycetemcomitans.

Authors:  V J Thomson; M K Bhattacharjee; D H Fine; K M Derbyshire; D H Figurski
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

7.  Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis.

Authors:  H D Schweizer
Journal:  Biotechniques       Date:  1993-11       Impact factor: 1.993

8.  Molecular cloning and characterization of the Salmonella enterica Serovar Paratyphi B rma Gene, which confers multiple drug resistance in Escherichia coli.

Authors:  Mahmoud A Yassien; Hosam E Ewis; Chung-Dar Lu; Ahmed T Abdelal
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

9.  Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore.

Authors:  T Schneiders; S G B Amyes; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli.

Authors:  Anthony M George; Ruth M Hall; H W Stokes
Journal:  Microbiology (Reading)       Date:  1995-08       Impact factor: 2.777

View more
  74 in total

1.  In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors:  Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae.

Authors:  Mark Veleba; Thamarai Schneiders
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Authors:  G L Drusano; William Hope; Alasdair MacGowan; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 4.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.

Authors:  C A Martin; A D Hoven; A M Cook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-06       Impact factor: 3.267

Review 7.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.

Authors:  M Hentschke; M Wolters; I Sobottka; H Rohde; M Aepfelbacher
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 9.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

10.  Risk Factors, Outcomes, and Mechanisms of Tigecycline-Nonsusceptible Klebsiella pneumoniae Bacteremia.

Authors:  Chih-Han Juan; Yi-Wei Huang; Yi-Tsung Lin; Tsuey-Ching Yang; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.